gpx-002
gpx-002: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Genprex, Inc. (GNPX) | Preclinical |
FDA Decisions
FDA_MeetingMeeting scheduled for Q1 2026 to discuss necessary IND-enabling preclinical studies.(GNPX)
Frequently asked questions
Who is developing gpx-002?
gpx-002 is being developed by Genprex, Inc..
What is gpx-002's latest FDA decision?
The most recent tracked FDA decision for gpx-002 is FDA_Meeting for Meeting scheduled for Q1 2026 to discuss necessary IND-enabling preclinical studies..
Get deeper analysis on gpx-002
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis